ФЕРРАРА Наполеон (US),КОРСИСААРИ Нина (US),МЭСС Роберт Д. (US)
申请号：
RU2013129450/15
公开号：
RU2013129450A
申请日:
2013.06.27
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. Use of an effective amount of VEGF-specific antagonist for preparation of a pharmaceutical composition for reducing the risk or delay the formation of tumor formation in a subject, which never clinically detected rak.2. Use according to claim. 1, which reduces the risk of tumor formation in subekta.3. Use according to claim. 1, which delays the formation of tumors in subekta.4. Use according to claim. 1, which reduces the risk or delays the formation of benign tumors or tumors in premalignant subekta.5. Use according to claim. 1, which reduces the risk or delays the formation of non-metastatic tumors in subekta.6. Use according to claim. 1, which reduces the risk or delays the formation of metastatic tumors in subekta.7. Use according to claim. 1, where a family history of said patient has cancer cases of hereditary cancer or polyps sindroma.8. Use according to claim. 1, where the VEGF-specific antagonist is monoterapiey.9. Use according to Claim. 1 further comprising monitoring the patient for education opuholi.10. Use according to Claim. 1, wherein the cancer is cancer of the gastrointestinal system, glioblastoma, colorectal cancer, breast cancer, ovarian, lung or pochek.11. Use according to Claim. 1 further comprising additional anticancer holding terapii.12. Use according to Claim. 1, wherein said VEGF-specific antagonist is selected from the group consisting of a polypeptide which specifically binds to VEGF, ribozymes, peptide antibodies, antisense oligonucleotides, small molecules and RNA aptamera.13. The use of claim. 12 wherein said polypeptide which specifically1. Применение эффективного количества VEGF-специфического антагониста для получения фармацевтической композиции для снижения риска образования или отсрочки образования опухоли у субъекта, у которого никогда клинически не детектировался рак.2. Применение по п. 1, которое снижает риск образования опухоли у субъекта.3. Применение по п. 1, которое отсрочивает образование опухоли у субъекта.4. Применен
